-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III

Symposia: Chronic Lymphocytic Leukemia: Basic and Translational Program: Oral and Poster Abstracts
Type: Poster
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Weiguo Han1*, Aisharya Bhattacharya1*, Wenzhi Ji, PhD2*, Basel A. Karim2*, Roman C. Sarott, PhD2*, Meredith Nix2*, Sai Gourisankar, PhD2*, Andrey Krokhotin3*, Sutapa Sinha, PhD1*, Zhiquan Wang, PhD1, Tait D. Shanafelt, MD4,5*, Sameer A. Parikh, MBBS1, Nathanael S. Gray, PhD2*, Gerald R. Crabtree, MD3,6* and Neil E. Kay, MD1,7

1Division of Hematology, Mayo Clinic, Rochester, MN
2Department of Chemical and Systems Biology, Stanford University, Stanford, CA
3Department of Pathology, Stanford University, Stanford, CA
4School of Medicine, Stanford University, Stanford, CA
5WellMD & WellPhD Center, Stanford University, Stanford, CA
6Department of Developmental Biology, Stanford University, Stanford, CA
7Department of Immunology, Mayo Clinic, Rochester, MN

Angimar Uriepero Palma, MD, MMSc1*, Melanie Mediavilla Varela, pH.D2*, Maria Elena Marquez, Ph.D3*, Wael Gamal2, Mohammad Ammad-ud-din, MD4*, Pablo Oppezzo, Ph.D5*, Eva Sahakian, PhD6* and Javier Pinilla-Ibarz, MD, PhD7*

1Department of Internal Medicine, Jefferson Einstein Hospital, Philadelphia, PA
2Immunology/Immune-Oncology, Moffitt Cancer Center, Tampa, FL
3Research Laboratory On Chronic Lymphocytic Leukemia. Institut Pasteur De Montevi, Montevideo, URY
4Department of Hematology/Oncology, Moffitt Cancer Center, Tampa, FL
5Institut Pasteur De Montevideo, Montevideo, URY
6Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
7Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL

Malte Knöll1*, Rashmi Priyadharshini Dheenadayalan, PhD2*, Deyan Y. Yosifov, PhD3*, Jialei Qi, MD4*, Christof Schneider, MD5*, Felix Seyfried, MD6*, Lueder Hinrich Meyer, MD6*, Paula Cramer, MD7*, Julia Von Tresckow, MD8*, Michael Hallek, MD9*, Barbara F. Eichhorst, MD9, Eugen Tausch, MD5*, Stephan Stilgenbauer, MD10 and Billy Jebaraj, PhD11*

1Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, AL, Germany
2University of Ulm, Ulm, Germany
3Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Baden-Württemberg, Germany
4University Hospital Ulm, Ulm, Germany
5Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany
6Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany
7Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany
8Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
9Department I of Internal Medicine, Faculty of Medicine and Cologne University Hospital, Cologne, Germany
10Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Germany
11Department of Internal Medicine III, Division of CLL, University of Ulm, Ulm, Baden Wurttemberg, Germany

Rebecca Svanberg Teglgaard, MD, PhD1,2*, Rudi Agius, PhD1*, Caspar da Cunha-Bang, MD, PhD1*, Tereza Faitova, MSc1*, Christian Brieghel, MD, PhD1*, Hans Jakob Hartling, MD, PhD2*, Hanne Vibeke Marquart, MD, PhD2*, Robert Schou Pedersen, MD, PhD3*, Christian Bjørn Poulsen, MD, PhD4*, Mark-David Levin5, Fransien De Boer, MD, PhD6*, Koen de Heer, MD, PhD7*, Rikke Kragh Lauridsen, MSc, PhD8*, Joanne Reekie, PhD8*, Anders Österborg, MD, PhD9*, Jeanette Lundin, MD, PhD9*, Magdalena Kättström, MD10*, Sisse Rye Ostrowski, MD, PhD, DMSc2,11* and Carsten Utoft Niemann, MD, PhD1,12*

1Department of Hematology, Rigshospitalet, Copenhagen, Denmark
2Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark
3Department of Hematology, Gødstrup Hospital, Herning, Denmark
4Department of Hematology, Zealand University Hospital, Roskilde, Denmark
5Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands
6Ikazia Hospital, Rotterdam, Netherlands
7Department of Internal Medicine, Flevoziekenhuis, Almere, Netherlands
8CHIP, Rigshospitalet, Copenhagen, Denmark
9Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
10Section of Hematology, Department of Medicine, Örebro University Hospital, Örebro, Sweden
11Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
12Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Ramon Massoni-Badosa, PhD1,2,3*, Joshua S. Schiffman, PhD1,2,3*, Barun Pradhan, PhD1,2,3*, Rebecca M. Murray, BS2,3,4*, Andrew H. Lipsky, MD5, Debra Van Egeren, PhD1,2,3*, Danny Luan, MD, MPH1, Shirley Chen, BS1*, Ronan Chaligne, PhD6*, Kai Beattie, BS1,2,3*, Alyssa Indart, PhD1,2,3*, Nada Chraiki, BS1,2,3*, Neville Dusaj, MD1,2,3*, Erica B. Bhavsar, BS1*, Chelston Ang, BS, MSc7, Anna S. Nam, MD8, Federico Gaiti, PhD9, Paulina Chamely, MSc1,2,3*, Nathaniel D. Omans, PhD1,2,3*, Preeti Trisal, MS10*, Anita K. Gandhi, PhD11, Kyu-Tae Kim, PhD12*, Rafael Schulman, BS13*, Franco Izzo, PhD14*, Gavriel Mullokandov, MD, PhD1,3*, Chingiz Underbayev, MD, PhD15*, Jan A. Burger, MD, PhD 16, Adrian Wiestner, MD15, Elisa Ten Hacken, PhD1, John N. Allan, MD1, Jennifer A. Woyach, MD17, Richard R. Furman, MD18 and Dan A. Landau, MD, PhD2,3,4*

1Division of Hematology and Medical Oncology, Department of Medicine and Meyer Cancer Center, Weill Cornell Medicine, New York, NY
2Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY
3New York Genome Center, New York, NY
4Division of Hematology and Medical Oncology and Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY
5Herbert Irving Comprehensive Cancer Center, New York-Presbyterian/Columbia University Medical Center, New York, NY
6Single Cell Analytics and Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY
7University of North Carolina School of Medicine, Chapel Hill, NC
8Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
9Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
10Bristol Myers Squibb, Summit, NJ
11Hematology, Translational Medicine, Bristol Myers Squibb, Summit, NJ
12Department of Physiology, Ajou University School of Medicine, Suwon, Korea, Republic of (South)
13SUNY-Upstate Medical College, New York, NY
14Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
15Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
16Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
17Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH
18Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY

Saurabh Yadav, PhD1,2, Sumbul Jawed Khan, PhD1*, Binu Kandathilparambil Sasi, PhD1,2, Elizabeth F. Cohen, MRes3*, Kiyomi Mashima, MD, PhD1,2, Hannah Cormier, BS1*, Stacey M. Fernandes, BS1*, Samantha J. Shupe, BS1*, Roberta Santos Azevedo4,5*, Mariia Mikhaleva, MD1*, Philippe Armand, MD, PhD1,2, David C. Fisher, MD1,2, Matthew S. Davids, MD, MMSc2,6, Inhye E. Ahn, MD1,2, Michael Y. Tolstorukov, PhD3*, Mark A. Murakami, MD1,2 and Jennifer R. Brown, MD, PhD1,2

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Medicine, Harvard Medical School, Boston, MA
3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Sao Paulo, AC, Brazil
5Department of Hematology, Hospital Nove de Julho, São Paulo, Brazil
6Department of Medical Oncology, Dana-Farber Cancer Institute, Inc., Boston, MA

Xiao Lu, MD1*, Yeqin Sha, MD2*, Xinyu Song, MD3*, Luomengjia Dai, MD2*, Ziyuan Zhou, MD2*, Hanning Tang, MD2*, Yi Miao, MD1*, Shuchao Qin, MD PHD1*, Yi Xia, MD, PhD2*, Tonglu Qiu, MD1*, Lei Fan4*, Jianyong Li, MD5 and Huayuan Zhu6*

1Lymphoma Center, Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2Lymphoma Center, Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
3School of Basic Medical Sciences of Nanjing Medical University, Nanjing, Jiangsu Province, China
4Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
5First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
6Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing, Jiangsu, China

Othman Al-Sawaf, MD1, Benjamin N. Locher2*, Friederike Christen2*, Sandra Robrecht, PhD3*, Can Zhang, PhD4*, Anna Maria Fink, MD4*, Eugen Tausch, MD5*, Christof Schneider, MD5*, Matthias Ritgen6*, Karl Anton Kreuzer7*, Coral Fustero2*, Raphael Hablesreiter8*, John F. Seymour, MBBS, PhD9, Piers Blombery, MBBS10, Lars Bullinger2, Brenda Chyla11, Hyun Yong Jin, PhD12*, Yanwen Jiang12*, Stephan Stilgenbauer, MD13, Barbara F. Eichhorst, MD14, Michael J. Hallek, MD15, Kirsten Fischer, MD3* and Frederik Damm2*

1Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany, Cologne, Germany
2Department of Hematology, Oncology, and Cancer Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
3Department I of Internal Medicine, Faculty of Medicine and Cologne University Hospital, Cologne, Germany
4Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany, Cologne, Germany, Cologne, Germany
5Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany
6Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
7Department I of Internal Medicine, University of Cologne, Cologne, Germany
8Department of Hematology, Oncology, and Cancer Immunology, Charité ? Universitätsmedizin Berlin, Berlin, Germany
9Peter MacCallum Cancer Center, Melbourne, Australia
10Peter Maccallum Cancer Centre, East Melbourne, VIC, Australia
11AbbVie Inc, North Chicago, IL
12Genentech, Inc., South San Francisco, CA
13Comprehensive Cancer Center Ulm, University of Ulm, Ulm, Germany
14University Hospital Cologne, Cologne, Germany
15Department 1 of Internal Medicine, University Hospital Cologne, Cologne, Germany

*signifies non-member of ASH